Protein kinase C delta is a substrate of tissue transglutaminase and a novel autoantigen in coeliac disease

Greg Byrne a,⁎, Michael Freeley b, Con Feighery c, Alex Whelan c, Aideen Long b

⁎ Corresponding author. Fax: +353 1 402 4995.
E-mail address: greg.byrne@dit.ie (G. Byrne).

Received 5 November 2012; accepted with revision 17 January 2013

Abstract Post-translational modification of proteins by deamidation or transamidation by tissue transglutaminase (tTG) has been suggested as a possible mechanism for the development of autoimmunity. Sequence analysis of protein kinase C delta (PKCδ) identified an amino acid motif that suggested the possibility that PKCδ was a glutamine substrate of tTG and MALDI-TOF analysis of synthesised peptides from PKCδ proved that this was the case. Polymerisation experiments using recombinant tTG and biotinylated hexapeptide substrate incorporation assays demonstrated that PKCδ is a substrate for tTG-mediated transamidation. Elevated levels of anti-PKCδ antibodies were detected in sera from patients with coeliac disease (p<0.0001) but not from patients with other autoimmune disorders. These data suggest that a subset of patients with coeliac disease produce autoantibodies against PKCδ and that this response may stem from a tTG–PKCδ substrate interaction.

© 2013 Elsevier Inc. All rights reserved.

1. Introduction

Coeliac disease is characterised by an inappropriate immune response to storage proteins in certain cereal cultivars. These prolamin proteins cause intestinal inflammation which is associated with gastrointestinal complaints as well as nutritional deficiencies associated with reduced absorptive surface in the small intestine [1]. The disorder has a broad spectrum of severity with some individuals having asymptomatic disease, others having fulminant responses to ingestion of cereals such as wheat, barley and rye. The best-characterised and most immunogenic prolamins for coeliac patients are gliadin and glutenin derived from wheat gluten [2].

The immune response against prolamins results in the activation of cereal-specific T cells that are of a Th1 cytokine profile and produce interferon gamma [3]. Inflammation in the small intestine leads to villous atrophy and...
crypt hyperplasia. Coeliac disease is also associated with humoral immune responses with antibodies produced against gluten and the autoantigen, tissue transglutaminase (tTG). The main reaction catalysed by tTG is the introduction of covalent ω-(c-glutamyl)lysine cross-links between a glutamine donor protein and a lysine donor protein [4]. In the absence of a suitable lysine donor and in the presence of water, tTG can deamidate its target glutamine, giving rise to a glutamic acid residue. This enzyme plays an important role in the disease through the site-specific deamidation of glutamine residues in the prolamin peptides. The tTG-mediated deamidation results in negatively charged residues at important anchor positions for binding to HLA-DQ2, the coeliac disease-associated MHC class II molecule. The increased binding of gliadin peptides to DQ2 results in more potent T cell responses to gliadin peptides [5].

The mechanisms by which tTG becomes an autoantigen are not well understood but the hapten carrier complex model as proposed by Ludwig Sollid suggests that covalent attachment of gluten peptides to tTG facilitates their uptake by tTG-specific B cells which receive help from gluten-specific T cells. However, some research has demonstrated the presence of tTG-reactive T cells in patients with coeliac disease which could drive the autoantibody response [6]. The recent development of highly sensitive and specific neoepitope assays where the antigen is a complex of tTG and antigen donor protein and a lysine donor protein [4]. In the absence of a suitable lysine donor and in the presence of water, tTG can deamidate its target glutamine, giving rise to a glutamic acid residue. This enzyme plays an important role in the disease through the site-specific deamidation of glutamine residues in the prolamin peptides. The tTG-mediated deamidation results in negatively charged residues at important anchor positions for binding to HLA-DQ2, the coeliac disease-associated MHC class II molecule. The increased binding of gliadin peptides to DQ2 results in more potent T cell responses to gliadin peptides [5].

The mechanisms by which tTG becomes an autoantigen are not well understood but the hapten carrier complex model as proposed by Ludwig Sollid suggests that covalent attachment of gluten peptides to tTG facilitates their uptake by tTG-specific B cells which receive help from gluten-specific T cells. However, some research has demonstrated the presence of tTG-reactive T cells in patients with coeliac disease which could drive the autoantibody response [6]. The recent development of highly sensitive and specific neoepitope assays where the antigen is a complex of tTG and antigen donor protein and a lysine donor protein [4]. In the absence of a suitable lysine donor and in the presence of water, tTG can deamidate its target glutamine, giving rise to a glutamic acid residue. This enzyme plays an important role in the disease through the site-specific deamidation of glutamine residues in the prolamin peptides. The tTG-mediated deamidation results in negatively charged residues at important anchor positions for binding to HLA-DQ2, the coeliac disease-associated MHC class II molecule. The increased binding of gliadin peptides to DQ2 results in more potent T cell responses to gliadin peptides [5].

The mechanisms by which tTG becomes an autoantigen are not well understood but the hapten carrier complex model as proposed by Ludwig Sollid suggests that covalent attachment of gluten peptides to tTG facilitates their uptake by tTG-specific B cells which receive help from gluten-specific T cells. However, some research has demonstrated the presence of tTG-reactive T cells in patients with coeliac disease which could drive the autoantibody response [6]. The recent development of highly sensitive and specific neoepitope assays where the antigen is a complex of tTG and antigen donor protein and a lysine donor protein [4]. In the absence of a suitable lysine donor and in the presence of water, tTG can deamidate its target glutamine, giving rise to a glutamic acid residue. This enzyme plays an important role in the disease through the site-specific deamidation of glutamine residues in the prolamin peptides. The tTG-mediated deamidation results in negatively charged residues at important anchor positions for binding to HLA-DQ2, the coeliac disease-associated MHC class II molecule. The increased binding of gliadin peptides to DQ2 results in more potent T cell responses to gliadin peptides [5].

The mechanisms by which tTG becomes an autoantigen are not well understood but the hapten carrier complex model as proposed by Ludwig Sollid suggests that covalent attachment of gluten peptides to tTG facilitates their uptake by tTG-specific B cells which receive help from gluten-specific T cells. However, some research has demonstrated the presence of tTG-reactive T cells in patients with coeliac disease which could drive the autoantibody response [6]. The recent development of highly sensitive and specific neoepitope assays where the antigen is a complex of tTG and antigen donor protein and a lysine donor protein [4]. In the absence of a suitable lysine donor and in the presence of water, tTG can deamidate its target glutamine, giving rise to a glutamic acid residue. This enzyme plays an important role in the disease through the site-specific deamidation of glutamine residues in the prolamin peptides. The tTG-mediated deamidation results in negatively charged residues at important anchor positions for binding to HLA-DQ2, the coeliac disease-associated MHC class II molecule. The increased binding of gliadin peptides to DQ2 results in more potent T cell responses to gliadin peptides [5].

The mechanisms by which tTG becomes an autoantigen are not well understood but the hapten carrier complex model as proposed by Ludwig Sollid suggests that covalent attachment of gluten peptides to tTG facilitates their uptake by tTG-specific B cells which receive help from gluten-specific T cells. However, some research has demonstrated the presence of tTG-reactive T cells in patients with coeliac disease which could drive the autoantibody response [6]. The recent development of highly sensitive and specific neoepitope assays where the antigen is a complex of tTG and antigen donor protein and a lysine donor protein [4]. In the absence of a suitable lysine donor and in the presence of water, tTG can deamidate its target glutamine, giving rise to a glutamic acid residue. This enzyme plays an important role in the disease through the site-specific deamidation of glutamine residues in the prolamin peptides. The tTG-mediated deamidation results in negatively charged residues at important anchor positions for binding to HLA-DQ2, the coeliac disease-associated MHC class II molecule. The increased binding of gliadin peptides to DQ2 results in more potent T cell responses to gliadin peptides [5].

The mechanisms by which tTG becomes an autoantigen are not well understood but the hapten carrier complex model as proposed by Ludwig Sollid suggests that covalent attachment of gluten peptides to tTG facilitates their uptake by tTG-specific B cells which receive help from gluten-specific T cells. However, some research has demonstrated the presence of tTG-reactive T cells in patients with coeliac disease which could drive the autoantibody response [6]. The recent development of highly sensitive and specific neoepitope assays where the antigen is a complex of tTG and antigen donor protein and a lysine donor protein [4]. In the absence of a suitable lysine donor and in the presence of water, tTG can deamidate its target glutamine, giving rise to a glutamic acid residue. This enzyme plays an important role in the disease through the site-specific deamidation of glutamine residues in the prolamin peptides. The tTG-mediated deamidation results in negatively charged residues at important anchor positions for binding to HLA-DQ2, the coeliac disease-associated MHC class II molecule. The increased binding of gliadin peptides to DQ2 results in more potent T cell responses to gliadin peptides [5].

The mechanisms by which tTG becomes an autoantigen are not well understood but the hapten carrier complex model as proposed by Ludwig Sollid suggests that covalent attachment of gluten peptides to tTG facilitates their uptake by tTG-specific B cells which receive help from gluten-specific T cells. However, some research has demonstrated the presence of tTG-reactive T cells in patients with coeliac disease which could drive the autoantibody response [6]. The recent development of highly sensitive and specific neoepitope assays where the antigen is a complex of tTG and antigen donor protein and a lysine donor protein [4]. In the absence of a suitable lysine donor and in the presence of water, tTG can deamidate its target glutamine, giving rise to a glutamic acid residue. This enzyme plays an important role in the disease through the site-specific deamidation of glutamine residues in the prolamin peptides. The tTG-mediated deamidation results in negatively charged residues at important anchor positions for binding to HLA-DQ2, the coeliac disease-associated MHC class II molecule. The increased binding of gliadin peptides to DQ2 results in more potent T cell responses to gliadin peptides [5].

The mechanisms by which tTG becomes an autoantigen are not well understood but the hapten carrier complex model as proposed by Ludwig Sollid suggests that covalent attachment of gluten peptides to tTG facilitates their uptake by tTG-specific B cells which receive help from gluten-specific T cells. However, some research has demonstrated the presence of tTG-reactive T cells in patients with coeliac disease which could drive the autoantibody response [6]. The recent development of highly sensitive and specific neoepitope assays where the antigen is a complex of tTG and antigen donor protein and a lysine donor protein [4]. In the absence of a suitable lysine donor and in the presence of water, tTG can deamidate its target glutamine, giving rise to a glutamic acid residue. This enzyme plays an important role in the disease through the site-specific deamidation of glutamine residues in the prolamin peptides. The tTG-mediated deamidation results in negatively charged residues at important anchor positions for binding to HLA-DQ2, the coeliac disease-associated MHC class II molecule. The increased binding of gliadin peptides to DQ2 results in more potent T cell responses to gliadin peptides [5].
concentration of 5 mM. Aliquots were removed for analysis after 8, 16, 45 and 96 min.

2.2. MALDI-ToF analysis

The samples were diluted in 0.1% trifluoroacetic acid and spotted directly on a MALDI target plate (“dry-droplet”) 1:1 with 5 mg/ml α-cyano-4-hydroxycinnamic acid as matrix. Each spectrum saved is the sum of approximately 1000 shots.

2.3. Polymerisation assays

One microgram of recombinant human PKCδ (Merck Bio-sciences) was incubated in the presence or absence of 1 μg recombinant human tTG (Roboscreen) in a reaction buffer containing 100 mM Tris, 10 mM CaCl₂, 10 mM DTT (pH 8) for 30 min at 37 °C.

2.4. Western blotting

Samples were separated on a 12% SDS-PAGE gel, transferred to a PVDF membrane and probed for polymerisation products using a 1:1000 dilution of mouse anti-human tTG CUB7402 (Labvision) or a 1:1000 dilution of mouse anti-human PKCδ (Santa Cruz). Bands were detected by the addition of rabbit anti-mouse HRP (Dako) and developed with a solution containing 12mls 100 mM Tris, 60 μl 30% H₂O₂. Reaction volumes were known tTG substrate assay a tube containing tTG, glutamine substrate probe and DTT (pH 8) at 37 °C for 30 min at 37 °C.

2.5. Hexapeptide substrate incorporation assays

Two N-terminally biotinylated hexapeptides, biotin-GQDPVR (Q-donor) and biotin-GNDPVK (K-donor), were used as probes to detect tTG-catalysed crosslinking. One microgram of recombinant human tTG (Roboscreen), 1 μg recombinant PKCδ (Calbiochem) and 2.5 μg of either lysine or glutamine substrate biotinylated hexapeptide probe were incubated in a reaction buffer containing 100 mM Tris, 10 mM CaCl₂, 10 mM DTT (pH 8) at 37 °C for 30 min (final volume 25 μl). In each assay a tube containing tTG, glutamine substrate probe and known tTG substrate N,N dimethylcasein (Sigma Aldrich) was included as a positive control. Reaction volumes were separated in a 12% SDS-PAGE gel and blotted onto a PVDF membrane. After blocking for 1 h with 5% non-fat dried milk containing 12mls 100 mM Tris, 60 μl 250 mM luminol, 26.6 μl 90 mM p-coumaric acid and 3.8 μl 30% H₂O₂.

2.6. Serum samples

Serum samples were collected from 30 patients with coeliac disease (11 male, 19 female; age 22–77, median 46). Diagnosis was based upon a positive endomyosal antibody test as well as elevated anti-tTG antibody levels and positive duodenal biopsy results. Sera from 15 healthy controls (2 male, 13 female; age 20–56; median 28) were also analysed. Disease control samples included samples from 8 patients with systemic lupus erythematosus (1 male, 7 female; age 4–41; median 27) and 15 samples from patients with granulomatosis with polyangiitis (9 male, 4 female; range 12–80; median 57). Ethical approval for this study was obtained from the joint ethics committee of St James’s and Tallaght hospitals.

2.7. PKCδ ELISA assay

ELISAs were performed by coating 96-well Maxisorp® plates (Nunc) with 1 μg per well of recombinant human PKCδ (Sigma-Aldrich) overnight at 4 °C. Wells were blocked with 1% HSA (Sigma-Aldrich) in PBS for 1 h and washed four times with PBS plus 0.1% Tween between each step. Human sera were diluted 1:20 with PBS plus 0.1% Tween followed by 1:1000 rabbit anti-human IgA conjugated to HRP (Dako). All antibody incubations were performed at room temperature for 1 h. ELISAs were developed using 3,3′,5,5′-tetramethylbenzidine liquid substrate system (Sigma-Aldrich) and were read at 450 nm in a spectrophotometer. A cut off for positivity was established as the mean+2 SD of the control population.

2.8. Statistical analysis

ELISA results from different sample groups were analysed using the non parametric Mann–Whitney U test.

3. Results

3.1. A peptide sequence from PKCδ is a substrate for deamidation by tTG

Analysis of the amino acid sequence of PKCδ identified a glutamine-containing sequence (MLIGQSPFH) that, according to the algorithm determined by Vader et al., represented a potential glutamine substrate sequence for tTG (Fig. 1). The motif QXP where X is any amino acid is reported to be a good substrate for tTG-mediated deamidation [5]. In order to test this hypothesis a peptide corresponding to the PKCδ sequence was synthesised and tested for deamidation by tTG using MALDI-ToF analysis. The known peptide substrates ALPTAQVPTDP from rat heat shock protein 20 and PFPQQLPYPKR from the DQ2-α-I epitope from α-gliadin were used as positive controls (Q residues in bold are known targets for deamidation by tTG). Deamidation can be calculated from the acquired MALDI-ToF mass spectra by calculating the shift of 1 Da equals one complete deamidation. The acquired MALDI-ToF mass spectra by calculating the centroid shift in the isotopic peak of the peptide. A complete shift of 1 Da equals one complete deamidation.

Incubation of tTG with PKCδ peptide MLIGQSPFH resulted in a centroid shift in the isotopic peak that was visible at the 45-minute time point indicating deamidation had taken place. While deamidation occurred in the PKCδ peptide, it was considerably slower than the control peptides, which both demonstrated deamidation after 8 min (Figs. 2a & b).

3.2. A peptide sequence from PKCδ is a crosslinked to 5BP in vitro

In order to determine whether the peptide MLIGQSPFH from PKCδ could act as a glutamine substrate for tTG in a transamidation reaction, the peptide was incubated in reaction buffer with tTG and 5BP, a well-characterised lysine substrate of tTG. Incorporation of 5BP into MLIGQSPFH
results in a 311 Da increase in mass that can be detected by MALDI-ToF. Analysis of the transamination reaction demonstrated an increase in mass corresponding to 5BP indicating that the PKCδ-derived peptide is a substrate for tTG-catalysed transamination (Fig. 2c).

3.3. Recombinant PKCδ is a glutamine substrate of tTG

The incorporation of biotinylated hexapeptide probes is an established method for the investigation of potential substrates of tTG [20]. Incorporation of lysine-containing probe (biotin-GNDPVK) indicates that a protein is a glutamine substrate of tTG, while the incorporation of glutamine-containing probe (biotin-GQDPVR) indicates that a protein is a lysine substrate of tTG. In these experiments, the incorporation of the probes was investigated by using extravidin peroxidase to detect biotinylated proteins in Western blots. The known glutamine substrate N′N′-dimethylcasein was used as a positive control.

Blots showed the presence of a tTG-dependant band in reactions containing the lysine substrate probe and PKCδ at the apparent molecular weight of tTG (~80 kDa). This result demonstrates that tTG can act as a lysine substrate for itself (Fig. 3). In the same lane, a biotinylated protein band was visible at high molecular weight, at the interface between stacking and resolving gels. No band was apparent at the molecular weight of recombinant PKCδ that was slightly lower at 77.5 kDa suggesting that PKCδ does not behave as a lysine substrate for tTG. In the reactions containing the glutamine substrate probe, PKCδ and tTG, a biotinylated band was visible at the molecular weight of PKCδ, indicating that it behaves as a glutamine substrate for tTG. Once again, a high molecular weight biotinylated band was apparent at the interface between stacking and resolving gels.

3.4. tTG catalyses the formation of high molecular weight PKCδ-tTG complexes

A reaction mixture containing PKCδ and tTG was incubated at 37 °C for 30 min and then subjected to Western blotting in order to characterise any resulting high molecular weight complexes. Western blots with a monoclonal anti-PKCδ

Figure 2. The peptide MLIGQSPF derived from PKCδ is deamidated and transamidated by tTG. a: Deamidation of the glutamine residue in the peptide can be calculated from the acquired MALDI-TOF mass spectra by calculating the centroid shift in the isotopic peak of the peptide. A complete shift of 1 Da equals one complete deamidation. Deamidation of MLIGQSPF is less than that of known deamidation targets PFPQQLPYPR from gliadin or ALPTAQVPTDP from rat small heat shock protein 20. b: Deamidation reactions represented as deamidations per peptide over 96 min. c: Transamidation with 5BP is reflected by a mass increment of 311 Da in the mass spectra.
antibody showed that incubation with tTG resulted in a reduction of the PKC$_\delta$ band intensity (Fig. 4a). A longer exposure time revealed higher molecular weight bands at ~160 kDa and at the stacking/resolving gel interface (Fig. 4b). Western blots of polymerisation reactions with a monoclonal anti-tTG antibody demonstrated that incubation of tTG and PKC$_\delta$ resulted in high molecular weight bands of equal size to those observed in the PKC$_\delta$ blots suggesting that the high molecular weight bands are tTG–PKC$_\delta$ heterodimers (Fig. 4c).

A band at the molecular weight of PKC$_\delta$ was also apparent after the polymerisation reaction occurred. The reason for the appearance of this band is unknown but the deamidation of PKC$_\delta$ by tTG could potentially result in the formation of a neoepitope that interacts with the anti-tTG monoclonal antibody.

3.5. Elevated levels of IgA anti-PKC$_\delta$ antibodies are detectable in sera from patients with coeliac disease but not in patients with other autoimmune conditions

ELISAs were performed with sera from patients with coeliac disease, granulomatosis with polyangiitis, systemic lupus erythematosus and control samples using recombinant PKC$_\delta$ as antigen. A highly significant ($p < 0.0001$) increase in IgA anti-PKC$_\delta$ was observed in the coeliac sera, but not in control sera or either autoimmune disease control (Fig. 5). There was no correlation between levels of anti-PKC$_\delta$...
were reported as having an atypical EMA pattern that is demonstrated elevated anti-PKCδ shown). Of the coeliac disease patient sera, 17 of 30 (57%) this enzyme-substrate interaction occurs in the full-length assays and polymerisation assays were used to show that deamidated and transamidated by tTG in MALDI-ToF.

In these experiments we have demonstrated that PKCδ is a signalling molecule which plays roles in diverse cellular pathways including cell growth, proliferation, differentiation and death [19]. In pancreatic cells, it has been demonstrated that PKCδ regulates the expression of tTG and that inhibition or silencing of PKCδ results in decreased tTG expression and a concomitant increase in autophagy in these cells [36]. Consistent with the finding that PKCδ regulates tTG expression, is the fact that the autoantigens

4. Discussion

In these experiments we have demonstrated that PKCδ is a glutamine substrate for tTG-mediated deamidation and transamidation. Amino acid sequence analysis identified a PKCδ substrate motif (QXP) in the catalytic domain of PKCδ at position 545 and a peptide corresponding to the MLIGQSPFH549 sequence of PKCδ was shown to be deamidated and transamidated by tTG in MALDI-ToF experiments. Biotinylated substrate probe incorporation assays and polymerisation assays were used to show that this enzyme-substrate interaction occurs in the full-length proteins and that TGG–PKCδ heterodimers are formed by the interaction. Finally, we have shown that a population of patients with coeliac disease has significantly elevated levels of IgA anti-PKCδ antibodies in their serum (p<0.001) and that these autoantibodies are not elevated in patients with systemic lupus erythematosus or granulomatosis with polyangiitis.

tTG is a multifunctional enzyme which displays crosslinking, deamidation, ATPase and protein disulphide isomerase activity [21,22]. The enzyme has been implicated in cellular processes as diverse as apoptosis [23], tissue repair [24], G-protein signalling [25] and cytokine activation [26,27]. The enzyme plays a role in the modification of gluten peptides in coeliac disease and, through this interaction, becomes the target of an IgA autoantibody response. The widely held belief is that tTG-catalysed gliadin-tTG heterodimers act as a hapten-like complexes which drive the production of anti-tTG antibodies facilitated by gliadin-specific T-cell help [28]. While tTG is the primary autoantigen in coeliac disease, some patients have been shown to produce elevated levels of antibodies against other self proteins including actin, desmin, reticulin, liver, brain and parietal cell antigens [29]. tTG-mediated post-translational modification of proteins by deamidation or transamidation is a possible mechanism for neoepitope generation and the development of autoimmunity. It is noteworthy that autoantigens (including actin, myosin and Histone 2B) from a variety of autoimmune diseases are substrates for tTG [30]. It is therefore conceivable that tTG-substrate interactions could result in epitope spreading to other autoantigens.

A number of proteins that are involved in the apoptotic process have been found to be autoantigens in disease states. The effective clearance of apoptotic cells is essential in the maintenance of tolerance and dysregulated phagocytosis of apoptotic cells has been implicated in the pathogenesis of SLE [31]. Significantly elevated levels of apoptosis have been observed in epithelial cells of the coeliac disease small intestine [32]. The main mechanism responsible for this phenomenon appears to be pro-inflammatory cytokine-induced increases in FAS/FASL expression [33]. PKCδ and tTG have both been described as having integral roles in the control of apoptosis [23,34]. Activation of tTG during apoptosis could result in significant modification of the antigenic profile of dying cells. Furthermore, crosslinking of proteins found in apoptotic blebs could increase the half-life of these proteins, thus increasing the exposure of these proteins to the immune system. It has been demonstrated that the induction of apoptosis in colon cancer cell lines is associated with shuttling of PKCδ to the cell membrane potentially making it available for tTG interaction and exposure to the immune system [35].

The production of anti-actin responses in coeliac disease has been associated with the atypical EMA pattern and more severe disease [11]. It is worth noting that in this study, PKCδ autoantibody levels tended to be higher in those patients that had an atypical EMA pattern (data not shown). Why some patients tend to produce antibody responses against other self-antigens is unknown but we propose a model whereby increased apoptosis in the coeliac small intestine results in the exposure of intracellular antigens on apoptotic cells which become available for tTG-mediated modification. This results in a longer protein half life or neoepitope formation, which culminates in autoantibody formation. Whether these autoantibodies play a role in coeliac disease pathogenesis is unknown but, given that PKCδ is normally intracellular, they are unlikely to interact with their target molecule except in the context of apoptosis or necrosis.

PKCδ is a signalling molecule which plays roles in diverse cellular pathways including cell growth, proliferation, differentiation and death [19]. In pancreatic cells, it has been demonstrated that PKCδ regulates the expression of tTG and that inhibition or silencing of PKCδ results in decreased tTG expression and a concomitant increase in autophagy in these cells [36]. Consistent with the finding that PKCδ regulates tTG expression, is the fact that the...
phenotype of the tTG knockout mouse [37] and the PKCδ knockout mouse [38] is remarkably similar. Interestingly, both tTGδ−/− and PKCδ−/− mice contain circulating autointo-
bodies and display immune complex glomerulonephritis and splenomegaly.

The discovery that PKCδ is a substrate for tTG cross-linking suggests the possibility that tTG-mediated cross-linking could act as a regulator of PKCδ activity in a negative feedback loop. The majority of intracellular tTG is assumed inactive due to a scarcity of Ca2+ but recent evidence has confirmed that during

Conflict of interest statement

The author(s) declare that there are no conflicts of interest.

Acknowledgments

The authors wish to thank Dr. J.W. Drijfhout, Leiden for providing the biotinylated hexapeptide probes. Dr. Marc Devocelle of RCSI, Dublin carried out peptide synthesis. We would also like to extend our thanks to Dr. Jorunn Stamnæs from the Centre for Immune Regulation, Institute of Immunology, University of Oslo who carried out the MALDI-ToF experiments.

References


